Stock Chart

GKOS

$163.75 +0.36%
Score: 72.3 HOLD
LEAPs: SELL $130
i
LEAPs Option Signal

Type: SELL growth_1yr
Strike: $130
Premium: $18.25
Expiry: Dec 18, 2026
Target: $130
Score: -99

LEAPs are long-term options (1+ year) with less time decay.
Pro
Screener
Vol: 0.84x (vs SPY: 0.8x | vs QQQ: 0.8x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Chart Pattern · as of Oct 02, 2026
Bear Pennant weak / forming — below our quality gate quality 59/100
A Bear Pennant is taking shape but hasn't passed our quality gate (60/100), so no projected path or levels are shown — only the forming rails on the chart below.
Historically breaks down 70% of the time (n=1,730). Measured-move targets failed our backtest — none shown.
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About GKOS - Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It …

Key Statistics

Market Cap $10B

This GKOS stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track GKOS's price movements with trendlines, gamma walls, and key support/resistance levels.